TP53 and breast cancer: Using a set of 16 different genetically engineered mouse models of breast cancer, Wellensten et al. [60] revealed that p53-deficient tumor cells can induce WNT-secreted ligands, increase circulating neutrophils and stimulate TAMs to produce IL-1β, thereby triggering CXCR4 systemic inflammation and leading to breast cancer cell metastasis.